US Patent

US11020407 — Corticosteroid containing foam compositions and method of manufacture thereof

Method of Use · Assigned to Mayne Pharma LLC · Expires 2036-11-30 · 11y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating various skin diseases by topically administering a foam composition containing a corticosteroid, such as halobetasol propionate.

USPTO Abstract

The present invention provides a method for treating various skin diseases by topically administering to a subject a composition formulated as a foamable composition which includes a corticosteroid, such as halobetasol. The composition may include a corticosteroid, ethyl alcohol, emulsifying wax, cetostearyl alcohol, polyoxyl 20 cetostearyl ether, water, benzoic acid and propellant.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3143 halobetasol-propionate

Patent Metadata

Patent number
US11020407
Jurisdiction
US
Classification
Method of Use
Expires
2036-11-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Mayne Pharma LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.